Results 91 to 100 of about 327,545 (257)

Prevention of acute chemotherapy-induced nausea and vomiting: the role of palonosetron

open access: yes, 2009
Emilio Bajetta, Sara Pusceddu, Valentina Guadalupi, Monika Ducceschi, Luigi CelioMedical Oncology Unit 2, Fondazione IRCCS “Istituto Nazionale dei Tumori”, Milan, ItalyAbstract: Prevention of nausea and vomiting is the main goal of ...
Sara Pusceddu   +3 more
core  

Nausea and Vomiting Management Barriers Questionnaire Dataset

open access: yes
Observational, descriptive study of patient perceptions of chemotherapy related nausea and vomiting. The patient sample consists of N=299 who completed socio-demographic and clinical items as well as a Nausea and Vomiting Management Barriers ...
Cella, Dave
core   +1 more source

A scoping review of adverse events associated with concomitant beta‐adrenoreceptor blockers and selective serotonin reuptake inhibitors

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Beta‐adrenoreceptor blockers (beta‐blockers) and selective serotonin reuptake inhibitors (SSRIs) are commonly used medications and often used together, such as for the treatment of anxiety. However, there is no recent review of any potential adverse events related to concomitant use of medicines from each group.
Ziyi Cai   +10 more
wiley   +1 more source

Symptom experiences during chemotherapy treatment—With focus on nausea and vomiting

open access: yes, 2006
Nausea and vomiting are common and well-studied symptoms in cancer care. Most previous studies have focused on the frequency and management of these symptoms.
Bergkvist, Karin   +5 more
core   +1 more source

Phase 1, open‐label, randomized study of the elecoglipron pharmacokinetic profile in healthy participants under fed and fasted conditions

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims Elecoglipron (AZD5004/ECC5004) is an oral small‐molecule glucagon‐like peptide‐1 receptor agonist (GLP‐1 RA) in development for weight management in people living with obesity or overweight and type 2 diabetes. This study aimed to characterize the pharmacokinetics (PK) profiles of two formulations of elecoglipron under fed and fasted conditions ...
Jianfeng Xu   +13 more
wiley   +1 more source

Relationship between nausea and vomiting and physical activity in patients with lung cancer undergoing first chemotherapy

open access: yesFrontiers in Oncology
ObjectiveNausea and vomiting are the distressing and debilitating side effects of chemotherapy. This study explores the relationship between the degree of nausea and vomiting and physical activity in patients with lung cancer during the first ...
Liandi Bai   +6 more
doaj   +1 more source

Systematic review of clinical trials and cohort studies evaluating HIV post‐exposure prophylaxis (PEP) regimens to inform updated Canadian guidelines

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Abstract Background We conducted a systematic review of clinical trials and cohort studies on HIV post‐exposure prophylaxis (PEP) regimens to inform updated 2025 Canadian guidelines. Methods We searched Medline and Embase (July 2017–June 2024) for studies reporting on: HIV acquisition, PEP completion, adverse events (AEs) leading to discontinuation and/
Stanley O. Onyegbule   +12 more
wiley   +1 more source

Frequency and Severity of Nausea and Vomiting in Pregnancy and the Related Factors among Pregnant Women

open access: yesنشریه پرستاری ایران, 2007
Background & Aim: Nausea and vomiting are the most common problems in early pregnancies which 50% to 80% of the women have experienced them in different degrees.
A. Soltani   +3 more
doaj  

An Exploratory study on factors related to nausea and vomiting in postoperative convalescence

open access: yes, 2012
[[abstract]]Purpose: The purpose of this study s is to investigate the factors related to post operative nausea and vomiting (PONV) for patients going through postoperative convalescence.
Zeng, Siouling
core  

Pharmacokinetic and pharmacodynamic interaction of enavogliflozin, a sodium‐glucose cotransporter 2 inhibitor, with glimepiride and metformin in healthy participants

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims Enavogliflozin, a sodium‐glucose cotransporter 2 inhibitor, is expected to be coadministered with antihyperglycaemic drugs with different mechanisms of action. This study aimed to investigate the pharmacokinetic (PK) and pharmacodynamic (PD) interactions between enavogliflozin, glimepiride and metformin.
Kyungrin Chang   +5 more
wiley   +1 more source

Home - About - Disclaimer - Privacy